Krasney Karen's Form 4 filing
Capricor Therapeutics, Inc. (CAPR) · filed May 4, 2026
- Accession no.
- 0001593086-26-000008
- Filed
- May 4, 2026
- Trade date
- May 1, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $792.5K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Krasney KarenCIK 0001593086 | Officer (EVP, GENERAL COUNSEL) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | MOption exerciseAcquired | +25,000 | $3.18 | +$79,500 | 55,547 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −25,000 | $31.70F2 | −$792,500 | 30,547 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 56,261 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.88 to $33.19, inclusive.
Referenced by the price of 1 transaction in Table I.